Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, cilt.16, sa.5, ss.384-388, 2025 (ESCI)
Aim: This study aimed to investigate the relationship between hematological parameters and treatment response in patients with advanced non-small cell lung cancer (NSCLC) treated with curative-intent chemoradiotherapy. Specifically, we evaluated whether markers like neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) correlate with radiologically assessed tumor size changes. Material and Methods: We conducted a retrospective analysis of 49 NSCLC patients treated between 2008 and 2014 at Atat & uuml;rk University School of Medicine. All patients received neoadjuvant chemotherapy followed by concurrent chemoradiotherapy. Hematological parameters, including NLR, PLR, and RDW, were collected before and after treatment. Tumor size was measured using PET-CT, MRI, or CT, and relationships between hematological markers and tumor size changes were analyzed using the Wilcoxon signed-rank test and Spearman's correlation, with significance at p < 0.05. Results: The cohort included 47 males (95.91%) and two females (4.08%), with a mean age of 62.88 +/- 9.91 years. Histopathologically, 79.6% had squamous cell carcinoma, and 20.4% had adenocarcinoma. Significant changes were observed in tumor size and several hematological parameters post-treatment (p < 0.05). However, no significant correlations were found between tumor size reduction and NLR, PLR, or RDW, except for a weak correlation with PDW (r = 0.301, p = 0.036). Discussion: While NLR, PLR, and RDW reflect systemic inflammatory responses, their predictive value for tumor size reduction in NSCLC patients treated with chemoradiotherapy appears limited. Further studies with larger sample sizes are needed to confirm these findings and improve prognostic assessment.